The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
Self-citationNew Multiple Sclerosis Phenotypic Classification
LUBLIN, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,277
Self-citationDobson, R., & Giovannoni, G. (2018) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,381
Thompson, A. J., Baranzini, S. E., Geurts, J. J. G., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,979
Self-citationThe Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationMultiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Berer, K., Gerdes, L. A., Cekanaviciute, E., Jia, X., Xiao, L., Xia, Z., Liu, C., Klotz, L., Stauffer, U., Baranzini, S. E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711233114 · Cited by 933
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
Benedict, R. H. B., Amato, M. P., DeLuca, J., & Geurts, J. J. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30277-5 · Cited by 787
New insights into the burden and costs of multiple sclerosis in Europe
Kobelt, G., Thompson, A. J., Berg, J., Gannedahl, M., Eriksson, J., the MSCOI Study Group, & Platform, T. E. M. S. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517694432 · Cited by 795
Self-citationOfatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar‐Or, A., Cohen, J. A., Comı, G., Correale, J. D., Coyle, P. K., Cross, A. H., Seze, J. D., Leppert, D., Montalbán, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 765
Self-citationMyelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes‐Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 799
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalbán, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comı, G., Derfuss, T. J., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 739
Self-citationDiagnosis of multiple sclerosis: progress and challenges
Brownlee, W. J., Hardy, T. A., Fazekas, F., & Miller, D. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30959-x · Cited by 701
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 711
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S. M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 696
Self-citationMultiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Self-citationBenkert, P., Meier, S., Schaedelin, S., Manouchehrinia, A., Yaldizli, Ö., Maceski, A., Oechtering, J., Achtnichts, L., Conen, D., Derfuss, T., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00009-6 · Cited by 657
Self-citationJakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H. B., Zipp, F., & Weinstock‐Guttman, B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 695
Multiple sclerosis: clinical aspects
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000622 · Cited by 620
Inefficient clearance of myelin debris by microglia impairs remyelinating processes
Lampron, A., Larochelle, A., Laflamme, N., Préfontaine, P., Plante, M.-M., Sánchez, M. G., Yong, V. W., Stys, P. K., Tremblay, M.-È., & Rivest, S. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141656 · Cited by 595
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
Petzold, A., Balcer, L. J., Calabresi, P. A., Costello, F., Frohman, T. C., Frohman, E. M., Martinez-Lapiscina, E. H., Green, A. J., Kardon, R., Outteryck, O., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30278-8 · Cited by 585
Self-citationProgressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J. D., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 609
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
The epidemiology of multiple sclerosis
Goodin, D. S. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 517
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S. S., Hobart, J. C., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A. L., & Vollmer, T. L. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 480
Self-citationDeep gray matter volume loss drives disability worsening in multiple sclerosis
Eshaghi, A., Prados, F., Brownlee, W. J., Altmann, D. R., Tur, C., Cardoso, M. J., Angelis, F. D., van de Pavert, S. H., Cawley, N., Stefano, N. D., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25145 · Cited by 454
Self-citationLUBLIN, F. D., Miller, D. H., Freedman, M. S., Cree, B., Wolinsky, J. S., Weiner, H. L., Lubetzki, C., Hartung, H., Montalbán, X., Uitdehaag, B. M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01314-8 · Cited by 448
Self-citationLong‐term evolution of multiple sclerosis disability in the treatment era
Cree, B., Gourraud, P., Oksenberg, J. R., Bevan, C. J., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A., Mowry, E. M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationDefining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K. A., Jokubaitis, V., Spelman, T. D., Havrdová, E., Horáková, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 435
Clinical Course of Multiple SclerosisPreprint
Klineova, S., & LUBLIN, F. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028928 · Cited by 453
Self-citationErickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 398
Harding, K. E., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T. P., Robertson, N. P., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 377
Multiple sclerosis: Pathology, diagnosis and treatments
Huang, W., Chen, W., & Zhang, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4410 · Cited by 389
Luchetti, S., Fransen, N. L., van Eden, C. G., Ramaglia, V., Mason, M., & Huitinga, I. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1818-y · Cited by 355
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 398
Martínez‐Lapiscina, E. H., Arnow, S., Wilson, J. A., Saidha, S., Preiningerova, J. L., Oberwahrenbrock, T., Brandt, A. U., Pablo, L. E., Guerrieri, S., González‐Suarez, I., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00068-5 · Cited by 334
Self-citationKapoor, R., Ho, P., Campbell, N., Chang, I., Deykin, A., Forrestal, F., Lucas, N., Yu, B., Arnold, D. L., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30069-3 · Cited by 333
Self-citationClassification, diagnosis, and differential diagnosis of multiple sclerosis
Sand, I. K. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000206 · Cited by 359
The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum
Gülöksüz, S., & van Os, J. (2017) · Psychological Medicine · doi:10.1017/s0033291717001775 · Cited by 369
Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis
Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901981 · Cited by 324
Self-citationEvolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Sørensen, P. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 320
Self-citationTourbah, A., Lebrun‐Frénay, C., Edan, G., Clanet, M., Papeix, C., Vukusic, S., Seze, J. D., Debouverie, M., Gout, O., Clavelou, P., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516667568 · Cited by 299
Self-citationProgressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Ontaneda, D., Thompson, A. J., Fox, R. J., & Cohen, J. A. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31320-4 · Cited by 298
Self-citationMemory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 290
Meier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5250 · Cited by 289
Self-citationRole of B Cells in Multiple Sclerosis and Related Disorders
Comı, G., Bar‐Or, A., Lassmann, H., Uccelli, A., Hartung, H., Montalbán, X., Sørensen, P. S., Hohlfeld, R., & Hauser, S. L. (2020) · Annals of Neurology · doi:10.1002/ana.25927 · Cited by 302
Self-citationTur, C., Carbonell‐Mirabent, P., Cobo‐Calvo, Á., Otero‐Romero, S., Arrambide, G., Midaglia, L. S., Castilló, J., Vidal‐Jordana, Á., Rodrı́guez‐Acevedo, B., Zabalza, A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4655 · Cited by 281
on behalf of the MAGNIMS study group, Sastre‐Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J. T., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 292
Self-citationDigital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 294
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J. T., Hellwig, K., Iacobaeus, E., Jensen, M. B., García‐Domínguez, J. M., Sousa, L., Rossi, N. D., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 273
Secondary Progressive Multiple Sclerosis
Cree, B., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Ramajo, A. P., Murphy, N., & Lassmann, H. (2021) · Neurology · doi:10.1212/wnl.0000000000012323 · Cited by 294
Self-citationExosomal microRNA signatures in multiple sclerosis reflect disease status
Ebrahimkhani, S., Vafaee, F., Young, P. E., Hur, S. S. J., Hawke, S. H., Devenney, E. M., Beadnall, H. N., Barnett, M. H., Suter, C. M., & Buckland, M. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-14301-3 · Cited by 265
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Eshaghi, A., Young, A. L., Wijeratne, P. A., Prados, F., Arnold, D. L., Narayanan, S., Guttmann, C. R. G., Barkhof, F., Alexander, D. C., Thompson, A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22265-2 · Cited by 281
Self-citationTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 257
Sharrack, B., Saccardi, R., Alexander, T., Badoglio, M., Burman, J., Farge, D., Greco, R., Jessop, H., Kazmi, M. A., Киргизов, К. И., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0684-0 · Cited by 262
Self-citationMultiple sclerosis, a treatable disease
Doshi, A., & Chataway, J. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s53 · Cited by 251
Defining reliable disability outcomes in multiple sclerosis
Kalinčík, T., Cutter, G., Spelman, T. D., Jokubaitis, V., Havrdová, E., Horáková, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2015) · Brain · doi:10.1093/brain/awv258 · Cited by 244
Self-citationde van der Schueren, M. A. E., Keller, H., Cederholm, T., Barazzoni, R., Compher, C., Correia, M. I. T. D., Gonzalez, M. C., Jager-Wittenaar, H., Pirlich, M., Steiber, A., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2019.12.022 · Cited by 242
Nutrition Facts in Multiple Sclerosis
Riccio, P., & Rossano, R. (2015) · ASN NEURO · doi:10.1177/1759091414568185 · Cited by 247
High doses of biotin in chronic progressive multiple sclerosis: A pilot study
Sedel, F., Papeix, C., Bellanger, A., Touitou, V., Lebrun‐Frénay, C., Galanaud, D., Gout, O., Lyon‐Caen, O., & Tourbah, A. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.01.005 · Cited by 230
ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis
Montalbán, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comı, G., Derfuss, T. J., Fazekas, F., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13536 · Cited by 233
Self-citationHarmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis
Müller, J., Cagol, A., Lorscheider, J., Tsagkas, C., Benkert, P., Yaldizli, Ö., Kühle, J., Derfuss, T. J., Sormani, M. P., Thompson, A. J., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3331 · Cited by 224
Self-citationClinical trials in progressive multiple sclerosis: lessons learned and future perspectives
Ontaneda, D., Fox, R. J., & Chataway, J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70264-9 · Cited by 223
Self-citationAlemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004313 · Cited by 221
Self-citationNatrajan, M. S., de la Fuente, A. G., Crawford, A. H., Linehan, E., Núñez, V., Johnson, K. R., Wu, T., Fitzgerald, D. C., Ricote, M., Bielekova, B., et al. (2015) · Brain · doi:10.1093/brain/awv289 · Cited by 225
Vision and vision-related outcome measures in multiple sclerosis
Balcer, L. J., Miller, D. H., Reingold, S. C., & Cohen, J. A. (2014) · Brain · doi:10.1093/brain/awu335 · Cited by 215
Self-citationPetrou, P., Kassis, I., Levin, N., Paul, F., Backner, Y., Benoliel, T., Oertel, F. C., Scheel, M., Halimi, M., Yaghmour, N. E., et al. (2020) · Brain · doi:10.1093/brain/awaa333 · Cited by 218
Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study
Eijlers, A. J. C., van Geest, Q., Dekker, I., Steenwijk, M. D., Meijer, K. A., Hulst, H. E., Barkhof, F., Uitdehaag, B. M. J., Schoonheim, M. M., & Geurts, J. J. G. (2018) · Brain · doi:10.1093/brain/awy202 · Cited by 222
Self-citationReich, D. S., Arnold, D. L., Vermersch, P., Bar-Or, A., Fox, R. J., Matta, A., Turner, T., Wallström, E., Zhang, X., Mareš, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00237-4 · Cited by 204
Self-citationCD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach, F., Richter, J., Pfeffer, L. K., Fehse, B., Berger, S. C., Reinhardt, S., Kühle, J., Badbaran, A., Rathje, K., Gagelmann, N., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.002 · Cited by 201
Clinical presentation and diagnosis of multiple sclerosis
Ford, H. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0292 · Cited by 199
Wiendl, H., Gold, R., Berger, T., Derfuss, T. J., Linker, R. A., Mäurer, M., Aktaş, O., Baum, K., Berghoff, M., Bittner, S., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211039648 · Cited by 207
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis
Meo, E. D., Portaccio, E., Giorgio, A., Ruano, L., Goretti, B., Niccolai, C., Patti, F., Chisari, C. G., Gallo, P., Grossi, P., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4920 · Cited by 190
Information processing speed in multiple sclerosis: Past, present, and future
Costa, S. L., Genova, H. M., DeLuca, J., & Chiaravalloti, N. D. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516645869 · Cited by 188
Granberg, T., Fan, Q., Treaba, C. A., Ouellette, R., Herranz, E., Mangeat, G., Louapre, C., Cohen-Adad, J., Klawiter, E. C., Sloane, J. A., et al. (2017) · Brain · doi:10.1093/brain/awx247 · Cited by 184
Clinical outcome measures in multiple sclerosis: A review
Inojosa, H., Schriefer, D., & Ziemssen, T. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102512 · Cited by 184
Page, E. L., Veillard, D., Laplaud, D. A., Hamonic, S., Wardi, R., Lebrun‐Frénay, C., Zagnoli, F., Wiertlewski, S., Deburghgraeve, V., Coustans, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61137-0 · Cited by 182
Multiple sclerosis: emerging epidemiological trends and redefining the clinical course
Portaccio, E., Magyari, M., Havrdová, E., Ruet, A., Brochet, B., Scalfari, A., Filippo, M. D., Tur, C., Montalbán, X., & Amato, M. P. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100977 · Cited by 196
Cagol, A., Schaedelin, S. A., Baraković, M., Benkert, P., Todea, R., Rahmanzadeh, R., Galbusera, R., Lu, P., Weigel, M., Melie‐García, L., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1025 · Cited by 187
Self-citationThe Role of Diet in Multiple Sclerosis: Mechanistic Connections and Current Evidence
Sand, I. K. (2018) · Current Nutrition Reports · doi:10.1007/s13668-018-0236-z · Cited by 181
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
Portaccio, E., Bellinvia, A., Fonderico, M., Pastò, L., Razzolini, L., Totaro, R., Spitaleri, D. L. A., Lugaresi, A., Cocco, E. E., ONOFRJ, M. C., et al. (2022) · Brain · doi:10.1093/brain/awac111 · Cited by 180
Neurodegeneration in multiple sclerosis
Mey, G. M., Mahajan, K. R., & DeSilva, T. M. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1583 · Cited by 188
Barro, C., Healy, B. C., Liu, Y., Saxena, S., Paul, A., Polgar‐Turcsanyi, M., Guttmann, C. R. G., Bakshi, R., Kropshofer, H., Weiner, H. L., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200052 · Cited by 187
Defining the clinical course of multiple sclerosis: The 2013 revisions
Jacques, F. H. (2015) · Neurology · doi:10.1212/01.wnl.0000462309.76486.c5 · Cited by 173
Updates and Advances in Multiple Sclerosis Neurotherapeutics
Amin, M., & Hersh, C. M. (2022) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0058 · Cited by 180
Disease modifying therapies for relapsing multiple sclerosis
Wingerchuk, D. M., & Weinshenker, B. G. (2016) · BMJ · doi:10.1136/bmj.i3518 · Cited by 174
Mariotto, S., Ferrari, S., Monaco, S., Benedetti, M. D., Schanda, K., Alberti, D., Farinazzo, A., Capra, R., Mancinelli, C. R., Rossi, N. D., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8635-4 · Cited by 166
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Seze, J. D., Maillart, É., Guéguen, A., Laplaud, D. A., Michel, L., Thouvenot, É., Zéphir, H., Zimmer, L., Biotti, D., & Liblau, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1004795 · Cited by 169
Promoting remyelination in multiple sclerosis
Cunniffe, N. G., & Coles, A. J. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09421-x · Cited by 172
The Role of Diet and Interventions on Multiple Sclerosis: A Review
Stoiloudis, P., Kesidou, E., Bakirtzis, C., Sintila, S.-A., Konstantinidou, N., Boziki, M. K., & Grigoriadis, N. (2022) · Nutrients · doi:10.3390/nu14061150 · Cited by 170
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach
Solomon, A. J., Arrambide, G., Brownlee, W. J., Flanagan, E. P., Amato, M. P., Amezcua, L., Banwell, B., Barkhof, F., Corboy, J. R., Correale, J. D., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00148-5 · Cited by 164
Self-citationCorboy, J. R., Fox, R. J., Kister, I., Cutter, G., Morgan, C. J., Seale, R., Engebretson, E., Gustafson, T., Miller, A., Bourdette, D., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00154-0 · Cited by 160
Self-citationSiponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
Gentile, A., Musella, A., Bullitta, S., Fresegna, D., Vito, F. D., Fantozzi, R., Piras, E., Gargano, F., Borsellino, G., Battistini, L., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0686-4 · Cited by 159
Multiple sclerosis, a treatable disease
Doshi, A., & Chataway, J. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-6-530 · Cited by 159
Kappos, L., Butzkueven, H., Wiendl, H., Spelman, T., Pellegrini, F., Chen, Y., Dong, Q., Koendgen, H., Belachew, S. M., Trojano, M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517709619 · Cited by 161
Self-citationImmunological Aspects of Approved MS Therapeutics
Rommer, P. S., Milo, R., Han, M. H., Satyanarayan, S., Sellner, J., Hauer, L., Illés, Z., Warnke, C., Laurent, S. A., Weber, M. S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01564 · Cited by 161
Self-citationExtra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders
Slominski, R. M., Tuckey, R. C., Manna, P. R., Jetten, A. M., Postlethwaite, A., Raman, C., & Slominski, A. T. (2020) · Genes & Immunity · doi:10.1038/s41435-020-0096-6 · Cited by 155
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
